ecancer

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

4 Oct 2019

Holistic management of patients with ALK-positive NSCLC

Rachel Thomas and Jackie Fenemore

3 Oct 2019

Precision medicine in ALK-positive NSCLC: Results from the BFAST trial

Prof Solange Peters and Prof Tony Mok

3 Oct 2019

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

28 Sep 2019

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

28 Sep 2019

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA

28 Sep 2019

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

28 Sep 2019

Comment: Osimertinib for EGFR-mutation positive NSCLC

Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain

28 Sep 2019

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Dr Marina Garassino - National Tumor Institute, Milan, Italy

28 Sep 2019

Important developments in radiation oncology

Dr Ana Botero - Memorial Healthcare System, Hollywood, FL, USA

26 Jul 2019

New standard of care for lung cancer patients with EGFR mutations

Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA

26 Jul 2019

Lung cancer screening and the management of the pulmonary nodule

Dr Mark Block - Memorial Healthcare System, Hollywood, FL, USA

26 Jul 2019

More from ecancer